July 9, 2022Open Access

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

AAApril W. ArmstrongUniversity of California, Los Angeles MGMelinda GooderhamQueen's University RWRichard B. WarrenNovartis (Switzerland)

Key Points

Key points are not available for this paper at this time.

Abstract

Deucravacitinib was superior to placebo and apremilast across multiple efficacy end points and was well tolerated in moderate to severe plaque psoriasis.

Demander à l'IA

Bookmark

View Full Paper